Search

everythinglearnresearchcommunity

for

Search:↓

Certain genetic variants in the androgen receptor are linked to higher PSA levels, potentially affecting prostate cancer screening outcomes.

Analog 23 is a promising compound for prostate cancer treatment.

Dutasteride reduces hospitalization and prostate cancer risk compared to finasteride, potentially offsetting its higher cost.

Finasteride reduces prostate cancer risk by 30% without affecting Gleason scores.

Medicines for enlarged prostate may raise the risk of breast growth and tenderness but not breast cancer.

Finasteride and dutasteride may lower melanoma risk, with teenage acne possibly indicating higher risk.

Finasteride reduces low-grade prostate cancer but may not be beneficial overall.

Finasteride improves prostate cancer prediction by adjusting kallikrein marker levels.

Continued research and awareness are needed to improve treatments for androgen-dependent diseases.

Antiandrogens might help prevent or treat COVID-19 by blocking the virus's entry into cells.

Finasteride and dutasteride reduce prostate cancer risk, but finasteride may increase higher-grade cancer risk.

Finasteride therapy reduces PSA levels and prostate size, helping diagnose prostate cancer.

The document concludes that accurately identifying leukemia types is crucial, and the risks of cancer from finasteride need careful evaluation against its benefits.

20(S)-Protopanaxadiol-aglycone may help prevent and treat prostate cancer by reducing androgen receptor activity.

PSA testing is a reliable method for detecting prostate cancer, and opioids may lower PSA levels, but triglycerides don't affect prostate cancer risk.

Provenge extends prostate cancer survival by about 4 months.

Dehydroepiandrosterone (DHEA) is a prohormone important for producing sex steroids and has potential health benefits.

Mutations in the androgen receptor gene cause androgen insensitivity, leading to female traits in genetically male individuals.

The document concludes that the 5 alpha-reductase enzymes are important in steroid metabolism and related to various human diseases, with inhibitors used to treat conditions like male pattern baldness and prostate issues.

The human type II 5α-reductase gene, linked to certain male health conditions, has a specific structure and low similarity to other related genes.

Male hormones like testosterone may make COVID-19 worse, and testing for sensitivity to these hormones could help predict how severe a patient's symptoms might be. Treatments that reduce these hormones are being explored.

5α-reductase is essential for male sexual development and its inhibitors have potential in treating various conditions related to hormone action.

Antiandrogens affect androgen-dependent body functions and are used for various medical conditions, with some risks like fetus feminization, but new forms like 17α-propylmesterolone show promise for acne without systemic effects.

Scientists made the first metal-based compounds from a nonsteroidal antiandrogen drug, which showed potential in fighting both hormone-dependent and independent prostate cancer cells.

Researchers found 63 genes linked to male-pattern baldness, which could help in understanding its biology and developing new treatments.

There is no clear recommendation for using selenium in cancer patients; it may be beneficial to correct low selenium levels before treatment.

Mitoxantrone with a corticosteroid helps manage symptoms for some advanced prostate cancer patients but doesn't extend life.

The length of the CAG repeat in the androgen receptor gene affects the risk and progression of prostate cancer, BPH, infertility, and undermasculinized genitalia.

Selective non-steroidal inhibitors of 5α-reductase type 1 can help treat DHT-related disorders.

Natural 5α-reduced glucocorticoids might be anti-inflammatory with fewer side effects than current options.